Article Text

Download PDFPDF
Safety and effectiveness of intravitreal dexamethasone implant in patients with ocular toxocariasis
  1. Limei Sun1,2,
  2. Li Huang1,2,
  3. Songshan Li1,2,
  4. Jinglin Lu1,2,
  5. Shuxin Zheng1,2,
  6. Xiaoyan Ding2,3
  1. 1Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Sun Yat-Sen University, Guangzhou, China
  2. 2Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China
  3. 3Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou, China
  1. Correspondence to Professor Xiaoyan Ding, Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou 510060, China; dingxy75{at}gmail.com

Abstract

Aims To evaluate the safety and effectiveness of intravitreal dexamethasone (DEX) implant in patients with active uveitis due to ocular toxocariasis (OT).

Methods Seventy-eight patients with OT were recruited in this retrospective study, including 51 patients in DEX group treated with intravitreal DEX implant and 27 patients in control group without intervention. The reduction of vitreous haze scores (VHS), the best-corrected visual acuity (BCVA) changes, intraocular pressure (IOP) and cataract progression and formation were recorded at baseline (V0), 1 (V1), 3 (V3) and 6 months (V6) after treatment in DEX group, and V0 and V6 in control group.

Results There was no change in VHS and BCVA in control group between V0 and V6. Better VHS (p=0.001) and BCVA (p=0.022) was achieved in DEX group; the rate of VHS=0 was 0%, 67.4%, 42.9% and 44.9% at V0, V1, V3 and V6, respectively (p<0.001), and the mean BCVA was improved from logMAR 1.5±0.9 to 1.2±0.9 at V1, 1.4±1.0 at V3 and 1.4±1.2 at V6. A favourable BCVA at V1 was associated with older age (p=0.038) and uninvolved macula (p=0.000) in DEX group. No significant difference in IOP elevation ≥10 mm Hg, cataract progression and formation between groups. More eyes needed retinal surgery in control group (p<0.001).

Conclusions This was the first study to investigate use of intravitreal DEX implant in OT patients, which can efficiently reduce ocular inflammation and improve BCVA in macular uninvolved patients.

  • Retina
  • Inflammation
  • Child health (paediatrics)
  • Treatment Medical

Data availability statement

No data are available.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • LS and LH are joint first authors.

  • LS and LH contributed equally.

  • Correction notice This article has been amended since it was first published. LS and LH contributed equally as first authors.

  • Contributors Study concept and design and drafting of the manuscript: XD, LS and LH. Data collection: LS, SL and SZ. Analysis and interpretation of the data: LS, LH, JL and XD. Revision of the manuscript: XD, LS and LH.

  • Funding This work was supported by the Fundamental Research Funds of the State Key Laboratory of Ophthalmology, as well as research funds from Sun Yat-sen University, grant number (15ykjxc22d; Guangzhou, Guangdong, China) and the National Natural Science Foundation of China, grant number (81700879).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.